PureTech Health (NASDAQ:PRTC) Shares Gap Up to $22.45
PureTech Health plc (NASDAQ:PRTC) shares gapped up to .45 before the market opened on Monday, rising from a previous close of .06. The stock last traded at .00 with a volume of 2,101 shares. Birch Hill Investment Advisors LLC recently acquired 302,000 shares in the company, valued at approximately $550,000. PureTech Health develops biopharmaceutical solutions and is currently advancing two products in clinical trials for treating serious health conditions.
PureTech Health plc (NASDAQ:PRTC - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $22.45, but opened at $23.06. PureTech Health shares last traded at $24.00, with a volume of 2,101 shares.
Get PureTech Health alerts:
PureTech Health Price Performance
The stock has a fifty day moving average price of $23.20 and a two-hundred day moving average price of $25.86.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC bought a new position in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 302,000 shares of the company's stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned about 1.26% of PureTech Health as of its most recent filing with the Securities and Exchange Commission (SEC). 0.04% of the stock is owned by institutional investors and hedge funds.
About PureTech Health
(Get Free Report)PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Recommended Stories
- Five stocks we like better than PureTech Health
- How Can Investors Benefit From After-Hours Trading
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- What Does a Stock Split Mean?
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Ride Out The Recession With These Dividend Kings
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Kamala Harris To Tank the Market? (From Paradigm Press) (Ad)
Should you invest $1,000 in PureTech Health right now?
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
